U.S. Markets closed

Synthetic Biologics, Inc. (SYN)

NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
0.6232-0.01 (-1.05%)
At close: 4:02PM EDT

0.6220 -0.00 (-0.19%)
After hours: 5:51PM EDT

People also watch
  • Addressing C-Diff is a national priority! Approx. a half million people in the U.S. get the infection each year (most over age 65) and as many as 3o thousand die within 30 days of being diagnosed. It is estimated to cost around $4.8 billion in additional health care costs per year. The usual treatment approach is to use IV Vancomycin (a strong antibiotic that comes with many adverse side effects). Any medication that shows promise of treating C-Diff successfully, without re-occurrence, is going to be a blockbuster financially, but, more importantly, save a great deal of misery and death.
  • Make that a 1 for 7 reverse split
  • Looking for a major pharmaceutical company to buyout SYN for $3 to $5/share. Patient investors will be richly rewarded in due course.
  • Given the FDA's recent action, I think it's time for the astute analysts to issue new reports and reiterate their buy/outperform ratings and price targets.
  • Very difficult to see SYN not making a big run north. if you guys have questions you should ask awe-someSTOCKS. They often respond to my emails which is helpful.
  • Why is SYN up today?
  • something is cooking. Can you smell it. This is going to POP. Good luck all longs
  • Let's see if Yahoo lets me link this:


    View and download 3548.pdf on DocDroid
  • SYN has to be one of the best hidden gems in the biotech sector with two Phase 3 ready therapies, SYN-004 and SYN-010. The latter received FDA Breakthrough Therapy (Fast Track) designation on May 11, 2017. All this with a market cap around $65 million and stock price under 55 cents/ share. This stock is way undervalued in my humble opinion.
  • Just for fun over the weekend, how many shares do you own and what is your average price/share?
  • SYN - announces a 7 for 1 split and Jeff Riley will issue more shares for his own ATM. Lather rinse repeat this is 3 times now.
  • When will the partnership(s) be announced?
  • New to the stock, what is their cash, how much money did they burn last qtr?
  • here we go again. Close at .70
  • Smell partnership tomorrow.
  • Time to run!
  • Amazing entry point for new Investors. Risk/reward profile is amazing considering the data from two compounds. If 004 gets approved this is $1.5B market cap which is 25x. Dilution wouldnot even matter if phase 3 delivers the same results.
  • Kaboom!
  • SYN-004 (Ribaxamase) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Prevention of Clostridium difficile Infection

    would think this will "perk" the interest of a "bigger player"-?Merck etc-CDiff is a scurge in hospitals/nursing homes/long term care facilities-and more and more becoming resistant to the standard antibiotics (Flagyl/Vancomycin)--this could be a ++$billion drug
  • (AXSM) Market Cap $92 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $92 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $92 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)

    Shares Out: 23.5 Million

    Anticipated Near-Term Clinical Milestones

    Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)

    Clinical Trial Readouts:

    -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

    -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

    -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)

    New Presentation May

    HUGE Pipeline targeting Billion Dollar Markets:

    AXS-05 Treatment Resistant Depression in Phase 3......Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.

    AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3.......No approved medication = unmet medical need. 2M patients in the U.S.

    AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status).......No approved drug = high unmet need. 80,000 new cases per year in the U.S.

    AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track).........7M patients in the U.S.

    AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 ......1.6M patients in the U.S.